Meeting
2018 ASCO Annual Meeting
Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
Authors
Paul K. Paik
Memorial Sloan Kettering Cancer Center, New York, NY
Paul K. Paik , Besnik Qeriqi , Linda Su Hyun Ahn , Michelle S. Ginsberg , Nidhi Tandon , Daniel McFarland , L. Austin Doyle , Elisa de Stanchina , Charles M. Rudin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02417701
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9098)
DOI
10.1200/JCO.2018.36.15_suppl.9098
Abstract #
9098
Poster Bd #
421
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
First Author: Paul K. Paik
Poster
2020 ASCO Virtual Scientific Program
Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
First Author: Paul K. Paik
Poster
2023 ASCO Annual Meeting
Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.
First Author: Joaquim Bosch-Barrera
Poster
2022 ASCO Annual Meeting
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
First Author: Mark Andrew Dickson